-
Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid
-
Yu-Mi Seo, Hyung-Jee Kim
-
Urogenit Tract Infect 2018;13(2):40-44. Published online August 31, 2018
-
-
-
 Abstract
 PDF
- Purpose: To determine if alpha-blocker monotherapy is effective on patients with benign prostatic hyperplasia (BPH) and prostatic inflammation.
Materials and Methods: Patients who were admitted for the treatment of lower urinary tract symptoms for 18 months were enrolled in this study. All were subjected to an International Prostate Symptom Score (IPSS) evaluation, prostate specific antigen analysis, urinalysis, residual urine testing, prostate massage, and transrectal prostate ultrasonography. The presence of inflammation in the secretion after the prostate massage was observed at high magnification. Patients with a leukocyte count of more than 15 were diagnosed as positive and classified as group 1 (experimental group), whereas those with a leukocyte count of less than 15 were diagnosed as negative and classified as group 2 (control group). Silodosin was administered (4 mg twice a day for two months).
Results: Group 1: After one and two months, there was no significant difference in the maximum urinary flow rate (Qmax) and post-void residual volume (PVR) compared to the baseline. The total IPSS was significantly improved over the 8-week study period. All symptoms except for Qmax and PVR showed significant improvement in the second month. Group 2: After one and two months, significant improvement was observed in all domains of the IPSS, and Qmax and PVR assessment, except for the PVR at one month.
Conclusions: In patients with BPH who have not been treated properly, other treatments based on prostatitis may be needed in addition to alpha blockers if there is inflammation on expressed secretion of prostate.
|
KAUTI
